ButaJect

This page contains information on ButaJect for veterinary use.
The information provided typically includes the following:
  • ButaJect Indications
  • Warnings and cautions for ButaJect
  • Direction and dosage information for ButaJect

ButaJect

This treatment applies to the following species:
Manufacturer: Butler Schein™ Animal Health

Phenylbutazone 20% Injection

Provides relief of inflammatory conditions of horses associated with the musculoskeletal system.

A non-hormonal anti-inflammatory agent unrelated to the corticosteroid anti-inflammatory agents.

Description

ButaJect (phenylbutazone) is a synthetic, non-hormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties.

Chemically, phenylbutazone is 4-butyl-1, 2-diphenyl-3, 5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones.

BACKGROUND PHARMACOLOGY: Kuzell,1,2,3 Payne,4 Fleming5 and Denko6 demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis, and various other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre,7 Domenjoz,8 Wilhelmi,9 and Yourish.10

Lieberman11 reported on the effective use of phenylbutazone in the treatment of painful conditions of the musculoskeletal system in dogs; including posterior paralysis associated with intervertebral disc syndrome, painful fractures, arthritis, and painful injuries to the limbs and joints. Joshua12 observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. Ogilivie and Sutter13 reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism, and other conditions associated with lameness and musculoskeletal weakness.

Camberos14 reported favorable results with phenylbutazone following intermittent treatment of thoroughbred horses for arthritis and chronic arthrosis (e.g. osteoarthritis of medial and distal bones of the hock, arthritis of stifle and hip, arthrosis of the spine, chronic hip pains, chronic pain in the trapezius muscles, and generalized arthritis). Results were less favorable in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Sutter reported favorable response in chronic equine arthritis, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx.

ButaJect Indications

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

Contraindications

Not for use in horses intended for food. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of drug allergy.

Precautions

Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agaranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routing blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate countermeasures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.

ButaJect Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Storage

Store in refrigerator between 2°C and 8°C (36°F and 46°F).

DOSAGE AND ADMINISTRATION: For horses only

INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

GUIDELINES TO SUCCESSFUL THERAPY

1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.

2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.

3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.

4. Many chronic conditions will respond to phenybutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.

How Supplied

INJECTION: 100 mL vials, 200 mg/mL (1 g/5mL). Each mL contains 200 mg of phenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0 and Water for Injection, q.s.

References

1. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: A.M.A. Arch. Int. Med. 92:646, 1953.

2. Kuzell, W.C., Schaffarzick, R.W., Brown, B., and Mankle, E.A.: Jour. Amer. Med. Assoc. 149:729, 1952.

3. Kuzell, W.C., and Schaffarzick, R.W.: Calif. Med. 77:319, 1952

4. Payne, R.W., Shetlar, M.R. Farr, C., Hellbaum, A.A. and Ishmael, W.K.T.: J. Lab. Clin. Med. 45:331, 1955.

5. Fleming, J., and Will, G.: Ann. Rheumat. Dis. 12:95, 1953.

6. Denko, C.W., and Ruml, D.: Amer. Practit. 6:1865, 1955.

7. Fabre, J., and Berger, A.: Semaine Hop. (Paris) 31:87, 1955.

8. Domenjoz, R., Theobald, W. and Morsdorf, K.: Arzneimittel-Forsch. 5:488, 1955.

9. Wilhelmi, G., and Pulver, R.: Arzneimittel-Forsch. 5:221, 1955.

10. Yourish, N., Paton, B., Brodie, B.B., and Burns, J.J.: A.M.A. Arch. Ophth. 53:264, 1955.

11. Lieberman, L.L.: Jour. Amer. Vet. Assoc. 125:128, 1954.

12. Joshua, J.O.: Vet. Rec. 68:60 (Jan. 21), 1956.

13. Ogilvie, F.B., and Sutter, M.D.: Vet. Med. 52:492-494, 1957.

14. Camberos, H.R.: Rev. Med. Vet. (Buenos Aires), 38:9, 1956.

15. Sutter, M.D.: Vet. Med. 53:83 (Feb.), 1958.

KEEP OUT OF REACH OF CHILDREN

ANADA 200-126, Approved by FDA

Manufactured for Butler Animal Health Supply, Dublin, Ohio 43017

NAC No.: 10822481

HENRY SCHEIN® ANIMAL HEALTH
400 METRO PLACE NORTH, DUBLIN, OH, 43017-7545
Telephone:   614-761-9095
Toll-Free:   1-855-724-3461
Website:   www.HenryScheinVet.com
Every effort has been made to ensure the accuracy of the ButaJect information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-04-11

(web5)